Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...

This article may contain affiliate links that Microsoft and/or the publisher may receive a commission from if you buy a product or service through those links.

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...

In August, the company announced that it had entered into a unique global partnership with Medtronic to connect Abbott's FreeStyle Libre CGM sensor with Medtronic’s automated insulin delivery ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Android application which receives Glucose values from multiple sources and provide Wear OS complications, Android Auto support, phone widgets/notifications and Tasker integration.

Global healthcare leader Abbott has developed Ensure Gold, a science-based nutrition solution available in both powder and ...